Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. (NCT05230810)

🧪 Interventions in This Study

• Alpelisib (DRUG)
• Tucatinib (DRUG)
• Fulvestrant (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (4 Sites)

• University of Colorado Cancer Center — Aurora, Colorado
• Cancer Care & Hematology-Fort Collins — Fort Collins, Colorado
• Louisiana State University Health Sciences Center — New Orleans, Louisiana
• University of Wisconsin Carbone Cancer Center — Madison, Wisconsin

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in HER2-positive Metastatic Breast Cancer

• Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer — Miami, Florida
• QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer — San Francisco, California

Explore by condition: All HER2-positive Metastatic Breast Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.